These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36415112)

  • 21. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
    Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.
    Hu JL; Yang J; Zhou YB; Li P; Han R; Fang DC
    Saudi J Gastroenterol; 2017; 23(5):275-280. PubMed ID: 28937021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection.
    Wu DC; Kuo CH; Tsay FW; Hsu WH; Chen A; Hsu PI
    Medicine (Baltimore); 2016 Mar; 95(11):e2698. PubMed ID: 26986096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
    Jung K; Jee SR; Lee MW; Koh M; Kim SJ; Lee J; Park MI
    Helicobacter; 2024; 29(3):e13084. PubMed ID: 38717034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
    Gao W; Hu F; Cheng H; Wang H; Yang Y; Liang H; Zhang S; Meng F; Cui M; Wei H; Sheng J; An HJ; Jiang B; Chen Y; Li Y; Zuo X; Gong J; Zhao P; Dong L; Wang B; Jiang K; Zhang G; Li J; Zhao Y; Gao H; Yang L
    Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(4):260-4. PubMed ID: 26879784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
    Nagahara A; Miwa H; Ogawa K; Kurosawa A; Ohkura R; Iida N; Sato N
    Helicobacter; 2000 Jun; 5(2):88-93. PubMed ID: 10849057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
    Chen KY; Lin TJ; Lin CL; Lee HC; Wang CK; Wu DC
    World J Gastroenterol; 2015 Sep; 21(36):10435-42. PubMed ID: 26420970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
    He XJ; Zeng XP; Jiang CS; Liu G; Li DZ; Wang W
    Arab J Gastroenterol; 2021 Mar; 22(1):47-51. PubMed ID: 33551347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for
    Kim SJ; Chung JW; Woo HS; Kim SY; Kim JH; Kim YJ; Kim KO; Kwon KA; Park DK
    World J Gastroenterol; 2019 Dec; 25(46):6790-6798. PubMed ID: 31857780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
    Gu L; Li S; He Y; Chen Y; Jiang Y; Peng Y; Liu X; Yang H
    Helicobacter; 2019 Aug; 24(4):e12594. PubMed ID: 31119830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
    Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
    Xie Y; Zhu Y; Zhou H; Lu ZF; Yang Z; Shu X; Guo XB; Fan HZ; Tang JH; Zeng XP; Wen JB; Li XQ; He XX; Ma JH; Liu DS; Huang CB; Xu NJ; Wang NR; Lu NH
    World J Gastroenterol; 2014 Aug; 20(32):11415-21. PubMed ID: 25170230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
    Sjomina O; Lielause A; Rūdule A; Vangravs R; Paršutins S; Poļaka I; Daugule I; Stonāns I; Park JY; Leja M
    Eur J Cancer Prev; 2022 Jul; 31(4):333-338. PubMed ID: 35471812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients.
    McNicholl AG; Bordin DS; Lucendo A; Fadeenko G; Fernandez MC; Voynovan I; Zakharova NV; Sarsenbaeva AS; Bujanda L; Perez-Aisa Á; Vologzhanina L; Zaytsev O; Ilchishina T; Coba C; Lasala JP; Alekseenko S; Modolell I; Molina-Infante J; Ruiz-Zorrilla Lopez R; Alonso-Galan H; Moreno NF; Hinojosa J; Santaella I; Varela P; Gonzalez-Cordero PL; Barrio J; Dominguez-Jimenez JL; Nuñez O; Alcedo J; Nyssen OP; Caldas M; Donday MG; Shvetz O; Megraud F; O'Morain C; Gisbert JP
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):89-98. PubMed ID: 30978536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.